Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

JERUSALEM, May 18, 2026 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the following investor conferences in May 2026. Event: H.C. Wainwright 4th Annual BioConnect Investor Conference Format: Fireside Chat and 1x1 Meetings Date: Tuesday, May 19, 2026 Time: 10:30 – 11:00AM ET Location: New York, NY Event: Rothschi

Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed

Jerusalem, May 8, 2026 - Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that it will host a conference call and webcast on Monday, May 11, 2026 at 8:30am ET to discuss interim clinical data from the first three patients treated in its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), also known as the REGAIN (Recurrent Glioblastoma A

First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA modular application process Enrollment of all 88 patients completed in the ReSTART trial, a U.S. multicenter pivotal study evaluating Alpha DaRT® for the treatment of recurrent cutaneous squamous cell carcinoma (cSCC), for which the Alpha DaRT has received Breakthrough Device Desig